Nintedanib Eg

Nintedanib, the active ingredient in Nintedanib Eg, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients where disease progression warrants antifibrotic therapy.

GNH USA supplies Nintedanib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nintedanib is used to target fibrotic and oncologic pathways in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth in patients with specific disease characteristics.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Elevated liver enzymes: increased ALT/AST levels on laboratory testing.

Serious or Rare Side Effects: - Hepatotoxicity: potential liver injury requiring monitoring. - Severe bleeding: heightened risk of gastrointestinal or other hemorrhage. - Cardiovascular events: includes myocardial infarction or ischemic heart disease. - Exacerbation of interstitial lung disease: worsening respiratory symptoms.

Before initiating therapy, clinicians should consider several safety measures. - Liver monitoring: assess hepatic function regularly and adjust therapy if transaminases rise. - Bleeding risk: evaluate patient history of hemorrhage and use caution with anticoagulants. - Cardiovascular assessment: screen for existing heart disease before treatment. - Pregnancy and lactation: avoid use due to unknown safety; discuss alternatives. - Severe hepatic impairment: contraindicated in patients with marked liver dysfunction. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑gp inhibitors (e.g., verapamil, amiodarone): can raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antacids that raise gastric pH: could affect absorption, monitor therapeutic response. - Concomitant antifibrotic agents: assess additive toxicity, especially hepatic.